Knowledge Intensive Services
Time from EMA approval to CT outcome for first indication vs. AMSR
This post launches a series of infographics focused on pricing and market access trends of rare disease treatments in France. Each post in this series zooms into a specific PMA trend by leveraging RADAR, CRA’s orphan drug data repository that includes all orphan drugs granted EMA approv...
Impact of medicare price “negotiation” program on small and large molecule medicines
The Inflation Reduction Act (IRA) directs the U.S. federal government to set a “Maximum Fair Price” (MFP) for the medicines with the highest spending in Medicare. The MFP will be implemented for selected small molecule drugs as early as nine years after approval, and as early as 13 year...
Assessment of the impact of earlier access to disease-modifying treatments with more convenient administration frequency in reducing the socioeconomic burden for multiple sclerosis patients in Europe
The socioeconomic impact of Multiple Sclerosis (MS) extends to various areas of a patient’s life including personal wellbeing and mental health, family life and planning, employment and the lives of caregivers, which is associated with a significant economic and societal burden. Advance...
Great cyber security audit offer for your schools or Trust
Are you confident in your school’s cyber security measures? In today’s digital age, safeguarding your school against cyber threats is paramount. Our goal is to help schools understand how to manage their risks and how to meet the latest technology standards, which is the minimum that sh...
‘Next Generation’ Bellissima DMS set to preview at FTA’s INFOFLEX
Cambridge,UK – Hamillroad Software, a global supplier of industry leading screening solutions, is all set to unveil new developments on their Bellissima DMS screening technology next month. The sneak preview comes ahead of the planned launch later in May at Drupa, when Bellissima’s next...
Redgate launches Enterprise edition of Redgate Monitor
Enhancing security and compliance and addressing the challenges of scale and complexity for large organisations. ...
Rene Haas’ comments on USA and Japan announcing two new university-corporate AI partnerships worth $110 million with support from Arm
Following the joint news release from United States Department of Commerce, the State Department and Japan’s Ministry of Education, Culture, Sports, Science and Technology, Arm released the following comment on Arm’s participation as a corporate sponsor: ...
Darktrace being sold to Thoma Bravo in the US for £5.315 billion
The acquisition is currently expected to complete during the third or fourth quarter of 2024. The parties have agreed that Darktrace retains its research and development capabilities in the UK and the Netherlands and that there will be no material restructurings or changes to Darktrace...
Sharing a free white paper to compare your IT support service
Breathe Technology wanted to share some valuable insights with you regarding the changing landscape of IT support for businesses and schools like yours. Our Managing Director recently penned a white paper outlining the shift from reactive break-fix models to proactive Full-Service MSP (...
Navigating payer challenges in rare disease
Clinical and economic evidence generation across rare diseases is challenging due to intrinsic disease characteristics, misalignment on treatment costs, and inadequate traditional evaluation frameworks. Therefore, rare disease products face unique payer challenges, which need to be comp...